Market News / Story
Daré Bioscience, Inc. Reports Phase 1 Topical Sildenafil PK Showing Much Lower Systemic Exposure
·
Daré Bioscience reported Phase 1 data: at a 71 mg topical dose, mean Cmax was ~187-fold lower and AUC ~33–34-fold lower vs 50 mg oral sildenafil; all treatment-emergent adverse events were mild with no serious events. Material Details #DetailAI Analyst View1Cmax ~187x lower vs 50 mg oralSuggests localized delivery with reduced systemic exposure, a key safety/labeling de-risker.2AUC ~33–34x lower topicallyLower overall exposure may cut systemic side effects; supports…